Lexi Ventures leads in gene tech venture investing.

Many forward thinkers agree that there will be more commercially realizable value produced by advances in the foundational technology of genetics, genomics, and synthetic biology (synbio) than in almost any other tech sector in the next 10 years.

Lexi Ventures invests at seed stage in startups reading, writing, and programming DNA, RNA, proteins, and cells to revolutionize diagnostics, therapeutics, and vaccines for human health and to optimize plants and microbes for consumer products, food, agriculture, mining and manufacturing.

Syndicate dealflow comes from the Lexi Ventures funds.